AU2002212225A1 - Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders - Google Patents

Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders

Info

Publication number
AU2002212225A1
AU2002212225A1 AU2002212225A AU1222502A AU2002212225A1 AU 2002212225 A1 AU2002212225 A1 AU 2002212225A1 AU 2002212225 A AU2002212225 A AU 2002212225A AU 1222502 A AU1222502 A AU 1222502A AU 2002212225 A1 AU2002212225 A1 AU 2002212225A1
Authority
AU
Australia
Prior art keywords
chemokine
bind
antibody
constructs
immunological disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002212225A
Inventor
Matthias Mack
Detlef Schloendorff
Michael Spring
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Research Munich GmbH
Original Assignee
Micromet GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/948,004 external-priority patent/US6723538B2/en
Application filed by Micromet GmbH filed Critical Micromet GmbH
Publication of AU2002212225A1 publication Critical patent/AU2002212225A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
AU2002212225A 2000-09-08 2001-09-10 Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders Abandoned AU2002212225A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP00119694.8 2000-09-08
EP00119694 2000-09-08
US09/948,004 US6723538B2 (en) 1999-03-11 2001-09-05 Bispecific antibody and chemokine receptor constructs
US09/948,004 2001-09-05
PCT/EP2001/010433 WO2002020615A2 (en) 2000-09-08 2001-09-10 Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders

Publications (1)

Publication Number Publication Date
AU2002212225A1 true AU2002212225A1 (en) 2002-03-22

Family

ID=32842663

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002212225A Abandoned AU2002212225A1 (en) 2000-09-08 2001-09-10 Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders

Country Status (10)

Country Link
EP (1) EP1317284A2 (en)
JP (1) JP2004508036A (en)
AU (1) AU2002212225A1 (en)
CA (1) CA2421842A1 (en)
HU (1) HUP0300942A2 (en)
NO (1) NO20031070L (en)
PL (1) PL366062A1 (en)
RU (1) RU2252786C2 (en)
WO (1) WO2002020615A2 (en)
ZA (1) ZA200301890B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002360073A1 (en) * 2001-12-21 2003-07-09 Micromet Ag Mono-and dual chemokine/cytokine constructs
NZ540196A (en) 2002-11-08 2008-09-26 Ablynx Nv Camelidae antibodies against imminoglobulin E and use thereof for the treatment of allergic disorders
AU2006297126A1 (en) 2005-09-30 2007-04-12 Government Of The United States Of America, As Represented By The Secretary Methods and compositions for modulating immune tolerance
CA2661782C (en) 2006-08-28 2019-04-16 La Jolla Institute For Allergy And Immunology Antagonistic human light-specific human monoclonal antibodies
PE20081785A1 (en) 2007-02-19 2009-01-12 Novartis Ag CYCLOHEXYL-AMIDE DERIVATIVES OF ARYL CARBOXYL ACID
NO2195023T3 (en) 2007-08-29 2018-08-04
EP2585089B1 (en) * 2010-06-28 2016-10-12 Universitätsklinikum Freiburg Blockade of ccl18 signaling via ccr6 as a therapeutic option in fibrotic diseases and cancer
TR201815863T4 (en) 2010-11-30 2018-11-21 Chugai Pharmaceutical Co Ltd Therapeutic agent that induces cytotoxicity.
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
CN106459206B (en) 2014-04-07 2024-06-07 中外制药株式会社 Immune-activating antigen binding molecules
BR112016026299A2 (en) 2014-05-13 2018-02-20 Chugai Seiyaku Kabushiki Kaisha The T-lymph cell redirection antigen joint molecule to the cell which has an immunosuppressive function
WO2017086367A1 (en) 2015-11-18 2017-05-26 中外製薬株式会社 Combination therapy using t cell redirection antigen binding molecule against cell having immunosuppressing function
WO2017086419A1 (en) 2015-11-18 2017-05-26 中外製薬株式会社 Method for enhancing humoral immune response
WO2017210749A1 (en) * 2016-06-10 2017-12-14 Adelaide Research & Innovation Pty Ltd Methods and products for treating autoimmune diseases
CN109970856B (en) 2017-12-27 2022-08-23 信达生物制药(苏州)有限公司 anti-LAG-3 antibodies and uses thereof
WO2021146272A1 (en) * 2020-01-13 2021-07-22 The Regents Of The University Of California Methods for treating viral infections

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1098664B1 (en) * 1998-07-22 2003-08-06 Osprey Pharmaceuticals Limited Conjugates for treating inflammatory disorders and associated tissue damage
WO2000053633A2 (en) * 1999-03-11 2000-09-14 Micromet Ag Antibody and chemokine constructs that are directed to ccr5, and their use for treating autoimmune diseases

Also Published As

Publication number Publication date
JP2004508036A (en) 2004-03-18
CA2421842A1 (en) 2002-03-14
NO20031070L (en) 2003-05-06
NO20031070D0 (en) 2003-03-07
HUP0300942A2 (en) 2003-09-29
ZA200301890B (en) 2004-03-16
EP1317284A2 (en) 2003-06-11
WO2002020615A3 (en) 2002-07-25
WO2002020615A2 (en) 2002-03-14
PL366062A1 (en) 2005-01-24
RU2252786C2 (en) 2005-05-27

Similar Documents

Publication Publication Date Title
AU2002212225A1 (en) Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders
IL151853A (en) Multivalent antibodies and uses thereof
HUP0302376A3 (en) Anti-tnf antibodies, compositions, methods and uses
AU2003257850A1 (en) ANTIBODY SPECIFIC TO CENTRAL Tau-PROTEIN
AU2607201A (en) Compensation for non-specific signals in quantitative immunoassays
MXPA03001590A (en) ANTIBODIES TO HUMAN IL-1bgr;.
AU2001243145A1 (en) Human g-protein chemokine receptor (ccr5) hdgnr10
IL153721A0 (en) Antibodies to human mcp-1
GB9927332D0 (en) Novel antibody and uses thereof
AU2001266604A1 (en) Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
AU7676300A (en) Human anti-adipocyte monoclonal antibodies and their use
AU2003302235A8 (en) Gp120 specific antigens, conjugates thereof, methods for their preparation and uses thereof
AU2608602A (en) Silensed anti-cd28 antibodies and use thereof
AU4100201A (en) Monoclonal antibodies to the human ldl receptor, their production and use
AU2001236887A1 (en) Antibody binding superficial zone protein and their uses in diagnosis and screening methods
AU2001244231A1 (en) Catalytic cracking materials based on zeolites itq-7 and their use in hydrocarbon cracking processes
AU2001297702A1 (en) Antibodies that immunospecifically bind to trail receptors
AU2002365894A1 (en) Antibodies to magmas and uses thereof
AU2001284899A1 (en) Methods and universal monoclonal antibody array
AU2001276581A1 (en) Compositions for inducing self-specific anti-ige antibodies and uses thereof
AU2002234488A1 (en) Single-strand antibody with improved stability
AU7099900A (en) Peptides that bind to urokinase receptor
AU2001245781A1 (en) Cd18-binding antibodies inhibit stenosis-related disorders
AU6904301A (en) Modified chemokine receptor ccr-3 and assay
AU2001274855A1 (en) Detection of antibodies to squalene in serum